BLOG

Abivax posts ulcerative colitis data, commits to phase 2b

Abivax has posted data from a phase 2a trial in patients with moderate-to-severe ulcerative colitis that are refractory to anti-TNF antibodies or corticosteroids. The trial linked ABX464 to improvements in mucosal healing and performance on a symptom scale, leading Abivax to commit to a phase 2b.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}